Medidata Solutions
announced that specialty contract research organization (CRO) QCTR Ltd. has selected Medidata CTMS, including its investigator site payment module, to manage the operations of all their clinical studies.
Scotland-based QCTR was founded in 2006 to fill an ndustry need for CRO expertise in central nervous system (CNS) clinical research. As their study pipeline grew, QCTR realized that a commercial trial management solution was necessary to efficiently do more with existing resource.
“Compared to other available systems, Medidata’s SaaS-based CTMS solution offered much greater value in terms of richness of features, speed of set-up, flexibility, ease-of-use and global accessibility—without requiring extensive up-front investment,” said Susan McGoldrick, Managing Director, QCTR. “It’s evident that Medidata CTMS was developed with CRO-specific needs in mind. We’re especially excited about the opportunities to more proactively manage the performance of investigator sites and streamline how we pay them—key aspects in our strategy to maintain our sites’ high satisfaction and patient recruitment excellence as we scale our business.”
QCTR anticipates that Medidata CTMS will greatly reduce the time and effort needed to track key milestones and operational metrics across their clinical studies and sites—both from the perspective of data entry as well as timely access to information and reports. As a result, study managers and monitors should be able to maintain a tight handle on issues despite increased study volumes and quickly follow up with sites.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.